Recent Updates
Recently added Catalysts
JAZZ Positive Sentiment Score: 70/100

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan...

Key Takeaway: Jazz Pharmaceuticals announced that it will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. CEO Bruce Cozadd will give an overview of the company and a business update on January 14, 2025. The webcast will be accessible through the Investors section of Jazz Pharmaceuticals' website, with a replay available for 30 days thereafter. The company aims to innovate and develop transformative medicines for patients with serious diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Jazz Pharmaceuticals is actively engaging with investors through presentations.
  • Company's commitment to innovation and transforming patient lives is highlighted.
  • They have a diverse portfolio including therapies for serious diseases.

Full Press Release Details

DUBLIN , Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the Company will webcast its corporate presentation at the 43 rd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd , chairman and chief executive officer, will provide an overview of the company and a business update on Tuesday, January 14, 2025 , at 9:45 a.m. PST / 5:45 p.m. GMT .
A live audio webcast of the presentation may be accessed via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations . A replay of the webcast will be available on the website for 30 days following the conference.
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Investors: Jeff Macdonald Executive Director, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland , +353 1 634 3211 U.S., +1 650 496 2717
Media: Kristin Bhavnani Head of Global Corporate Communications Jazz Pharmaceuticals plc [email protected] Ireland , +353 1 637 2141 U.S., +1 215 867 4948
SOURCE Jazz Pharmaceuticals plc

21 %

Frequently Asked Questions

When is Jazz Pharmaceuticals' presentation at the J.P. Morgan Healthcare Conference?

The presentation is on January 14, 2025, at 9:45 a.m. PST.

How can I access the webcast of Jazz Pharmaceuticals' presentation?

The webcast can be accessed via the Investors section on Jazz Pharmaceuticals' website.

How long will the webcast replay be available after the conference?

The replay will be available for 30 days following the conference.

What is the focus of Jazz Pharmaceuticals' research and development?

Jazz Pharmaceuticals focuses on developing medicines for serious diseases with limited options.

Where is Jazz Pharmaceuticals headquartered?

Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

Last updated: Dec 17, 2024